Conditions such as congestive heart failure and type 1 diabetes both have very large impact on human health and are associated with major societal costs and burdens. They are also key candidates for treatments using cell and tissue-based regenerative medicine therapeutics. Treatments based on transplanting cells or small patches of tissue which could help repairing the damaged organ, preventing further loss of function or even enabling recovery. This opportunity gives hope that for the possibility to in the future being able to treat conditions that today lead to several millions of premature deaths and disabilities every year and which are associated with ever increasing healthcare costs.
Fluicell’s partnership program for regenerative medicine development, BioRej® Advance, focuses on bioprinted tissue therapeutics targeting high impact diseases lacking adequate treatment options. The microtissues are produced using Fluicell 3D single-cell bioprinting platform Biopixlar® and are created on porous membranes that could be transplanted into the patients body directly on the treated organ. The platform serves as a technological framework for development of advanced therapeutics in almost any type of disease area using any type of cells.
We are now actively seeking partners who would like to join forces with us in developing next generation of regenerative medicine therapeutics to enable new advances for human health. Fluicell i currently developing artificial pancreatic islets for type 1 diabetes treatment, with the goal to initiate preclinical in vivo development in 2024. Read more about the program in our whitepaper.
Why partner with Fluicell?
What we offer.
- Pioneering technologies for developing detailed biological tissues with realistic cellular architecture and functionality.
- An innovative research team with a broad expertise across many different fields.
- Trust-based relationships based on mutual benefit.
What we seek.
- Pipeline partners to develop engineered tissue products based on Fluicell’s proprietary bioprinting technology.
- Academic partners to explore bioprinted tissue therapeutics in vivo.
Fluicell’s microfluidic high resolution bioprinting technology Biopixlar combined with the ability to create tissues on transferable membranes is ideal for soft tissue regenerative medicine applications. We are initially focusing on creating engineered tissue therapeutics in the areas of cardiac muscle repair, pancreatic tissue therapies and ocular regenerative medicine. However, the BioRej Advance program is open for exploration into any kind of soft tissue therapeutics research and development.
The BioRej® program is designed to address a wide range of therapeutic and research challenges. Target applications can involve almost any type of cell, including both autologous and allogenic stem cells. Because of Fluicell’s microfluidic bioprinting technology requires only very little cellular material to create high cell density tissues, the BioRej Advance program is ideal for applications involving scarce and valuable cells, including patient material.
BioRej Advance Highlights
The innovative 3D single-cell bioprinting platform Biopixlar is capable of creating detailed multicellular microtissues. With Biopixlar, it is possible to recreate the microscopic cellular architecture of actual biological tissues. Furthermore, since Biopixlar prints cells without using any bioink, it is possible to directly control the microenvironment around the printed cells. Both the ability of create highly detailed tissues and to precisely control the cellular microenvironment are essential features when creating tissues with an actual biological functionality that could be transplanted into a human body.
Biopixlar’s microfluidic bioprinting technology also leads to very little mechanical stress, ensuring a very high survivability rate of the bioprinted cells.Learn More
Why porous membranes?
The use of porous membranes adds several important components to the regenerative medicine platform. The purpose structure of the membrane ensures that the printed cells have access to nutrients providing long term viability of the constructed tissues. The membranes are also important to create a tissue that can be transferred from the production stage and be transplanted into a patient. The ability of the membrane to keep the bioprinted structure intact has the potential to increase the survivability of the transplanted tissue and thereby improving its functionality.
The combination of high-resolution bioprinting with transferable membranes should result in transplated tissues that better matches the target organ, both in terms of having the correct cell types and the correct cellular architecture. Several of the porous membranes we use in the BioRej Advance program are approved for use in humans and are therefore well suited for therapeutic development.Learn More